Fresenius Medical Care AG (Fresenius Medical Care AG) Short-Term Debt & Capital Lease Obligation : $1,703 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Fresenius Medical Care AG Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Fresenius Medical Care AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,703 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Fresenius Medical Care AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11,438 Mil.

Fresenius Medical Care AG Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Fresenius Medical Care AG's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius Medical Care AG Short-Term Debt & Capital Lease Obligation Chart

Fresenius Medical Care AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

3,619.81

2,064.22

2,921.35

2,136.29

1,702.90

Fresenius Medical Care AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															2,136.29	2,214.03	2,445.85	2,035.66	1,702.90

Fresenius Medical Care AG Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Fresenius Medical Care AG Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

FMCQF:USA FME:Italy FMEd:UK 0H9X:UK FME:Germany FMEA:Germany FME:Germany FME:Germany FMEA:Germany FME:Germany FMSC34:Brazil FME:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.freseniusmedicalcare.com

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Executives

Helen Pring Giza

Board of Directors